Catheter News and Research

RSS

In medicine, a catheter is a tube that can be inserted into a body cavity, duct, or vessel. Catheters . In most uses, a catheter is a thin, flexible tube ("soft" catheter), though in some uses, it is a larger, solid ("hard") catheter. A catheter left inside the body, either temporarily or permanently, may be referred to as an indwelling catheter. A permanently inserted catheter may be referred to as a permcath.

Reperfusion therapy proves beneficial for patients with heart attacks

The wider use of reperfusion therapy in patients with heart attack (AMI) can save millions of lives in Europe. Effective reperfusion therapy in an AMI patient can cut the individual risk of dying by half.

1 Sep 2009

Endosense raises USD 36 million in Series B financing

Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing. Edmond de Rothschild Investment Partners (EdRIP) led the round, with additional participation from Neomed, Gimv, VI Partners (VI), Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.

1 Sep 2009

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

31 Aug 2009

Ochsner Medical Center selected to participate as an FDA investigative site in the PARTNER clinical trial

On Tuesday, August 11, 2009, an 82-year old New Orleans resident with severe aortic stenosis successfully had a heart valve replaced at Ochsner Medical Center using the same technique as angioplasty, a far cry from the traditional open heart procedure. Patients who are considered high-risk or non-operable for conventional open heart valve surgery now have a potential new research option available regionally only through The John Ochsner Heart & Vascular Institute.

28 Aug 2009

Distribution agreement signed between Cardiovascular Systems and Asahi Intecc

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, has signed an exclusive distribution agreement with Asahi Intecc Co., Ltd., based in Japan, to market its peripheral guide wire line in the United States.

28 Aug 2009

FBN features Prescient Medical's CEO

Prescient Medical Inc. announced that CEO Patricia Scheller, appeared on FOX Business Network (FBN) to discuss the company's groundbreaking products and recent achievement of CE Mark approval for their vProtect(TM) Luminal Shield Stent System.

27 Aug 2009

CardioMEMS raises $22.1M to fund clinical trial of its heart failure pressure measurement system

CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.

27 Aug 2009

Urologix announces fiscal 2009 fourth-quarter and full-year financial results

Urologix®, Inc. (NASDAQ:ULGX), a medical device company focused on developing, manufacturing and marketing Cooled ThermoTherapy™ systems, a durable and effective catheter based in-office alternative to drugs or surgery for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the fourth quarter ended June 30, 2009 and for fiscal year 2009.

26 Aug 2009

Medline Industries' Foley catheter management system helps minimize CAUTI risk

In an effort to help clinicians reduce the risk of catheter-associated urinary tract infections (CAUTI), Medline Industries, Inc. today launched a ground-breaking Foley catheter management system featuring a reengineered catheter tray coupled with an evidence-based clinical education program.

25 Aug 2009

New minimally invasive procedure to treat ruptured brain aneurysm developed

Researchers in Finland have identified an effective new treatment option for patients who have suffered a ruptured brain aneurysm, a potentially life-threatening event. Results of the new study on stent-assisted coil embolization were published today in the online edition of Radiology.

25 Aug 2009

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.

24 Aug 2009

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

24 Aug 2009

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Physicians at The Mount Sinai Medical Center were the first in the country to perform a non-surgical procedure using sutures to tie off a left atrial appendage (LAA), which is the source of blood clots leading to stroke in patients with atrial fibrillation (AFib). AFib is the most common sustained heart-rhythm disorder in the United States.

24 Aug 2009

TCT Featured Clinical Trials to be presented on September 24 in San Francisco

A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

21 Aug 2009

Cardiovascular Systems' revenues in fourth-quarter of 2009 increases to $15.7 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fourth quarter and fiscal year ended June 30, 2009.

19 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Neovasc reports Q2 2009 financials

"During the second quarter we continued to make significant progress in executing on our strategic initiatives adopted late last year," said Alexei Marko, chief executive officer of Neovasc. "We are especially pleased at the growing traction we are seeing in our tissue business, where our decision to focus on our specialty products and services is beginning to bear fruit, with increases in tissue sales already evident.

19 Aug 2009

Bioheart's executive management team strengthened by the inclusion of board members

Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.

19 Aug 2009

Nfocus Neuromedical obtains CE approval for vascular reconstruction device

Nfocus Neuromedical Inc. announced today that its CardioVasc Advantage Vascular Reconstruction Device has been granted CE Mark approval by the European Notified Body, G-Med.

13 Aug 2009

New method for neonatal icus reduces infection and lung distress in preemies

A new method for improving quality of care can reduce hospital-acquired infections and chronic respiratory distress with oxygen dependency in premature infants in neonatal ICUs, according to a new study in CMAJ (Canadian Medical Association Journal).

11 Aug 2009

Catheter News and Research

Further Reading

Reperfusion therapy proves beneficial for patients with heart attacks

Endosense raises USD 36 million in Series B financing

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

Ochsner Medical Center selected to participate as an FDA investigative site in the PARTNER clinical trial

Distribution agreement signed between Cardiovascular Systems and Asahi Intecc

FBN features Prescient Medical's CEO

CardioMEMS raises $22.1M to fund clinical trial of its heart failure pressure measurement system

Urologix announces fiscal 2009 fourth-quarter and full-year financial results

Medline Industries' Foley catheter management system helps minimize CAUTI risk

New minimally invasive procedure to treat ruptured brain aneurysm developed

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

TCT Featured Clinical Trials to be presented on September 24 in San Francisco

Cardiovascular Systems' revenues in fourth-quarter of 2009 increases to $15.7 million

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Neovasc reports Q2 2009 financials

Bioheart's executive management team strengthened by the inclusion of board members

Nfocus Neuromedical obtains CE approval for vascular reconstruction device

New method for neonatal icus reduces infection and lung distress in preemies

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News